nogapendekin alfa inbakicept-pmln
AssetAlso called Nogapendekin Alfa, N-803, ANKTIVA, NAI
IL-15 superagonist enhances natural killer and T-cell responses to support vaccine-mediated cancer prevention.
- Stage
- Approved
- Modality
- Protein or enzyme
- Target
- IL2RB
- 26
- Indications
- 14
- Trials
- 3
- Developers
Approved by the FDA on Apr 22, 2024 (BLA761336). 2 approvals stand. FDA
Indications
26Bcg-unresponsive non-muscle invasive bladder cancer
Approved, FDA
Bladder cancer
Approved, news.google.com
Bcg-unresponsive non-muscle invasive bladder cancer with carcinoma in situ
Approved, businesswire.com
23 more
In the full profile
- Target and mechanism4
- Owner and partners4
- Trials14
- Evidence for its targets3
- Competitors12
- Signals11
Every asset’s record: target, stage, trials and the evidence behind it.